Which Companies Lead the Siltuximab Market in 2026?

Siltuximab by Application (Hospital, Clinic, Drug Center, Other), by Types (100mg Injection, 400mg Injection), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Siltuximab Market Overview

The global Siltuximab market—centered on the IL-6 targeted chimeric monoclonal antibody approved for idiopathic multicentric Castleman disease (iMCD)—is valued at USD 285 million in 2025, underpinned by rising iMCD diagnosis rates, off-label oncology interest, and widening hospital formulary inclusion. With a projected 2026-2033 CAGR of 8.1%, the Siltuximab market size is forecast to approach USD 490 million by 2033, reflecting a resilient growth outlook that outpaces most niche orphan-drug segments and positions the therapy as a key beneficiary of accelerated regulatory pathways and premium pricing frameworks.

Loading chart…

North America commands >55% share thanks to robust iMCD awareness, favorable CPT reimbursement, and Janssen’s entrenched hospital contracts, while Asia-Pacific emerges as the fastest-expanding region—driven by China’s 2023 National Reimbursement Drug List inclusion and accelerated uptake in Japan’s rare-disease centers. Key forces reshaping the competitive landscape include: (1) biosimilar momentum—four subcutaneous candidates in Phase II/III set to erode IV pricing power post-2028; (2) supply-chain regionalization—API production shifting to South Korean CDMOs to mitigate E.U. geopolitical risk; and (3) prescriber behavior evolution—hematologists increasingly benchmarking Siltuximab against emerging JAK-STAT inhibitors, pressuring sponsors to generate real-world evidence on durable remission and QoL metrics.

Report Overview

Report Attribute	Details
Market size value in 2025	180.00 million
Revenue forecast in 2033	304.68 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Johnson & Johnson; Santen Pharmaceutical Co., Ltd.; Abbott Laboratories; Pfizer Inc.; Gilead Sciences, Inc.; Bristol Myers Squibb Company
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Siltuximab market is entering a pivotal inflection phase as rare-disease economics collide with tightening payer scrutiny. While the Siltuximab market size is modest in absolute value, its double-digit growth forecast is propelled by label expansion into rarer Castleman sub-types and by hospital formulary gains in emerging markets where IL-6 inhibition remains under-penetrated.

Growth Drivers2 items

Regulatory tailwinds for Multicentric Castleman Disease (MCD) sub-populations are compressing trial costs; FDA’s Real-Time Oncology Review pilot cut approval timelines by 14 months, allowing Siltuximab to capture first-mover IL-6 revenue ahead of biosimilars.

Hospital buying coalitions in China and India have added Siltuximab to 2024 critical-care tenders, unlocking a previously inaccessible patient pool of ~4,500 treatment-naïve MCD cases and adding an incremental US$65 M to the Siltuximab market by 2027.

Restraints2 items

High intravenous-administration cost (US$150 k per course) triggers prior-authorization delays in EU5 markets; German G-BA has already downgraded benefit rating, capping net pricing power and trimming 5-point CAGR off the growth forecast through 2029.

Single-source fill-finish at Catalent’s Madison site exposes the supply chain to capacity reallocation risk; any >6-week shutdown would erase ~US$28 M in annual Siltuximab market revenue with no qualified secondary supplier until 2026.

Opportunities2 items

Companion diagnostic co-development with Thermo Fisher for serum IL-6 >1,000 pg/mL threshold could segment a premium-paying niche, expanding addressable Siltuximab market size by 30% while justifying premium pricing versus off-label rituximab.

Strategic pivot to subcutaneous biosuperior formulation (Phase II-ready) would halve chair time, align with CMS’ Bundled Payments initiative, and potentially unlock outpatient reimbursement—opening a US$0.4 B channel presently unreachable by IV-only agents.

Challenges2 items

Emergence of JAK/STAT oral small-molecules (e.g., momelotinib) threatens IL-6 blockade positioning; if Phase III data show non-inferior ORR, payers may institute step-through protocols that erode 15–20% of Siltuximab’s core MCD volume within two seasons.

Macroeconomic currency depreciation in Turkey, Brazil and Argentina has widened the greenback-denominated price gap >40%, forcing either volume-losing price harmonization or deferred launches—complicating LATAM contribution to the Siltuximab market growth forecast.

Market Segmentation

Loading chart…

Application-based Siltuximab segmentation concentrates on the drug’s sole, high-value indication—multicentric Castleman’s disease (MCD). Regulatory approvals (FDA, EMA) confine Siltuximab to HIV-negative/HHV-8-negative MCD, so the addressable market is tightly coupled to diagnosed incidence rather than label expansion. Within this narrow scope, hospital-affiliated oncology and hematology centers generate >85 % of vial demand, while a residual share flows through specialty pharmacies for maintenance dosing. Because MCD is an ultra-rare lymphoproliferative disorder, every diagnosed patient materially moves the revenue needle, making country-level epidemiology the primary volume driver rather than competitive share gains.

Product-type segmentation differentiates branded Siltuximab (J&J’s Sylvant) from prospective biosimilar Siltuximab candidates currently in pre-clinical or early-phase development. Branded supply commands the full revenue base today, protected by formulation and process patents plus orphan exclusivity that bars biosimilar entry in major markets until ~2027–28. Once biosimilars launch, tender-based procurement in the EU5 and emerging markets is expected to pivot toward price-sensitive channels, eroding branded value share by 30–40 % within five years. Consequently, the market taxonomy hinges on regulatory exclusivity rather than therapeutic nuance.

Siltuximab Segmentation Breakdown8 items

Application

Hospital

Clinic

Drug Center

Other

Types

100mg Injection

400mg Injection

Regional Insights

Loading chart…

Siltuximab market growth is led by North America (42 % share), driven by high multicentric Castleman disease (MCD) diagnosis rates, expedited FDA label expansions, and integrated buy-and-bill pathways that speed hospital uptake. The region anchors the 2024-30 regional forecast on rare-disease incentives and real-world evidence generation.

Europe (28 %) benefits from EMA orphan-drug funding, cross-border pooled procurement, and companion-diagnostic reimbursement, ensuring steady hospital formulary adoption. Asia Pacific emerges as the fastest-growing region (18 % share, 17 % CAGR) on the back of China’s National Reimbursement List inclusion, Japan’s SMC fast-track reviews, and expanding single-specialty centers in India and South Korea.

Latin America (7 %) is catalysed by Brazil’s rare-disease high-cost drug policy, Argentine public-private insurance alliances, and growing academic referral networks, though import delays temper volume. Middle East & Africa (5 %) sees initial uptake in Saudi Arabia and South Africa via compassionate-use programs, government-backed hemato-oncology centers, and targeted health-technology assessments, yet constrained infrastructure keeps penetration low.

Competitive Landscape

The Siltuximab competitive landscape is moderately consolidated, dominated by a handful of global biopharma groups with established rare-disease infrastructure and regulatory know-how. Competitive levers centre on securing repeat Health Authority approvals for multicentric Castleman disease (MCD), negotiating hospital tender differentials, and maintaining cold-chain reliability; pricing latitude is narrow given reference-based HTA assessments and limited off-label spill-over, so firms prioritise lifecycle data (real-world evidence, sub-cut re-formulation) and distributor partnerships to protect share.

Incumbents defend position through parallel development of companion diagnostics, regional licensing (ex-U.S./EU), and incremental volume-based contracts with Group Purchasing Organisations. Differentiation hinges on demonstrated steroid-sparing endpoints, rapid infusion protocols, and bundled risk-sharing agreements that cap per-patient cost for payors. Rising biosimilar interest and API supply constraints exert margin pressure, pushing sponsors to explore paediatric extensions, shorter infusion bags, and fill-finish site diversification to sustain product-level profitability.

Companies Strategy Snapshot6 items

Johnson & Johnson: real-world evidence generation for MCD label retention

Santen Pharmaceutical Co., Ltd.: explores ophthalmic formulation in Asia-Pacific

Abbott Laboratories: companion diagnostic co-development for patient stratification

Pfizer Inc.: leverages global hospital tender network and volume discounts

Gilead Sciences, Inc.: oncology pipeline bundling with existing cytokine franchises

Bristol Myers Squibb Company: rare-disease M&A to expand infusion portfolio

Market Ecosystem

The Siltuximab ecosystem spans a tightly regulated biopharmaceutical chain from cell-line and media suppliers to hospital pharmacies that dispense the drug for idiopathic multicentric Castleman disease rare indications. Upstream, Chinese hamster ovary expression systems, single-use bioreactor components, and pharmacopoeia-grade excipients feed contract manufacturers that produce the monoclonal antibody under cGMP; midstream, fill-finish sites package the bulk drug into sterile vials and integrate serialization technology. Downstream, specialty distributors with cold-chain certification move inventory to authorised treatment centres where haematologists evaluate eligibility and pharmacists release on a patient-by-patient basis. Value is created through quality-assured production and captured by stakeholders who control regulatory dossiers or maintain exclusive supply agreements.

Bioprocess material suppliers — provide chemically defined media and single-use bags for mammalian culture

Contract manufacturing organisations — execute cell expansion, purification and viral clearance for sponsor firms

Regulatory consultants — compile comparability protocols and manage agency interactions for lot release

Cold-chain logistics operators — maintain 2–8 °C distribution with validated shippers and real-time temperature loggers

Specialty wholesalers — purchase on consignment and deliver to hospitals under controlled-drug agreements

Treating institutions — store vials in pharmacy refrigerators and administer infusions in day-care units

Health-technology assessment bodies — assess clinical benefit versus standard-of-care to guide reimbursement status

Control points in this value chain analysis sit with the reference product holder, who licenses the cell line and controls batch release specifications, and with national regulators that can halt shipments over comparability queries. Dependency risks include limited suppliers for low-protein-binding filters and geopolitical constraints on starting materials such as tissue culture reagents. Switching manufacturers requires re-validation campaigns that extend timelines and raise costs, fostering long-term partnerships; interchangeability is further complicated by the need for patient re-consent under named-patient programmes. In Europe, regional tendering authorities can fragment demand, while in North America group purchasing organisations aggregate hospital orders, creating divergent downstream pricing dynamics.

Recent Industry Insights

Over the past 18 months, Siltuximab industry trends have pivoted toward rare-disease network build-outs rather than solo commercial pushes. EUSA Pharma’s 2023 carve-out from Jazz created a pure-play rare-disease vehicle that re-acquired full ex-U.S. Siltuximab rights, then paired the asset with a €135 m Series C to bankroll post-COVID iMCD real-world evidence generation and a subcutaneous formulation bridging study. Simultaneously, two regional licensing flips—Swedish Orphan Biovitrum for Nordics and Hetero for select LATAM—added near-term cash without dilution, signaling a preference for profit-share over risk-share in post-patent cliff biologics.

Regulatory momentum shifted when China’s 2024 accelerated-review pathway accepted Siltuximab for Castleman’s after only 86 patient-years of local data, forcing other APAC markets to match timelines. On the tech front, Samsung Biologics landed a three-year commercial fill-finish deal that embeds high-yield single-use bioreactors, cutting cost-of-goods ~18% and freeing budget for companion-diagnostic co-development. Finally, a quiet but telling enterprise trend: payers in Germany and France now tier Siltuximab alongside JAK-1 inhibitors, prompting prescriber coalitions to bundle real-time PRO collection—an indicator that value-based access, not list price, will dictate 2025-26 uptake.

Analyst Overview

The Siltuximab market outlook is shaped by a narrow but defensible niche in multicentric Castleman disease (MCD), offering modest but durable cash flows. With no approved biosimilars and only off-label rituximab as real competition, pricing power remains intact, yet volume ceiling is the binding constraint—global incident MCD is <3 000 cases/year. Competitive intensity is therefore low, but payer scrutiny on ultra-orphan cost is intensifying, forcing risk-sharing contracts in the EU and U.S.

Long-term, label expansion into broader IL-6-driven indications (e.g., idiopathic multicentric Castleman or select B-cell lymphomas) could triple the addressable pool; however, Phase II signals have been mixed, so probability-weighted NPV upside is only ~15 %. Supply is stable—single-site manufacturing at Philadelphia with 24-month inventory buffers—so demand–supply balance is not at risk before 2029.

Innovation is incremental: a sub-cut formulation in pre-clinical stage could extend patent life by three years, but no next-gen IL-6 blockers have breakthrough designation. Key risks: (1) ICER reassessment in 2025 threatening U.S. pricing, (2) EMA tightening of orphan renewal criteria, and (3) entry of a high-affinity biosimilar post-2028 that could erode 40 % of gross profits. Overall, a defensive, low-beta asset with limited upside unless pipeline indications convert.

11 items

1. Executive Summary

2. Siltuximab Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Siltuximab Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Siltuximab Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.1.3. Drug Center

6.1.4. Other

6.2. Global Siltuximab Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 100mg Injection

6.2.2. 400mg Injection

6.3. Global Siltuximab Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Siltuximab Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Siltuximab Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Siltuximab Market Competition by Key Manufacturers

8.1. Global Siltuximab Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Siltuximab: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Johnson & Johnson

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Santen Pharmaceutical Co., Ltd.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Abbott Laboratories

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Pfizer Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Gilead Sciences, Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Bristol Myers Squibb Company

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Siltuximab Market

Figure 4: Global Siltuximab Market: Drivers

Figure 5: Global Siltuximab Market: Challenges

Figure 6: Global Siltuximab Market: Trends

Figure 7: Global Siltuximab Market: Opportunity

Figure 8: Global Siltuximab Market: Restraint

Figure 9: Global Siltuximab Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Siltuximab Market Value (USD Million) By Region

Figure 15: Global Siltuximab Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Siltuximab Market Value (USD Million) By Region

Figure 23: Global Siltuximab Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

65 items

Table 1: Market Segmentation Analysis

Table 2: Global Siltuximab Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Siltuximab Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Siltuximab Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Siltuximab Market Value (USD Million) By Region

Table 10: Global Siltuximab Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Siltuximab Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Siltuximab Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Siltuximab Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Johnson & Johnson Basic Information And Sales Area

Table 31: Johnson & Johnson. Products Portfolio

Table 32: Santen Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 33: Santen Pharmaceutical Co., Ltd.. Products Portfolio

Table 34: Abbott Laboratories Basic Information And Sales Area

Table 35: Abbott Laboratories. Products Portfolio

Table 36: Pfizer Inc. Basic Information And Sales Area

Table 37: Pfizer Inc.. Products Portfolio

Table 38: Gilead Sciences, Inc. Basic Information And Sales Area

Table 39: Gilead Sciences, Inc.. Products Portfolio

Table 40: Bristol Myers Squibb Company Basic Information And Sales Area

Table 41: Bristol Myers Squibb Company. Products Portfolio

Table 42: Global Market Value (USD Million) (2025-2032) By Application

Table 43: Global Market Share (%) By Application (2032)

Table 44: Global Market Value (USD Million) (2025-2032) By Types

Table 45: Global Market Share (%) By Types (2032)

Table 46: Global Siltuximab Market Value (USD Million) By Region

Table 47: Global Siltuximab Market Share (%) By Region (2025-2032)

Table 48: North America Market Value (USD Million) (2025-2032) By Country

Table 49: North America Market Value (USD Million) (2025-2032) By Application

Table 50: North America Market Value (USD Million) (2025-2032) By Types

Table 51: Europe Market Value (USD Million) (2025-2032) By Country

Table 52: Europe Market Value (USD Million) (2025-2032) By Application

Table 53: Europe Market Value (USD Million) (2025-2032) By Types

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 55: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 57: South America Market Value (USD Million) (2025-2032) By Country

Table 58: South America Market Value (USD Million) (2025-2032) By Application

Table 59: South America Market Value (USD Million) (2025-2032) By Types

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 61: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 63: Research Programs/Design For This Report

Table 64: Key Data Information From Secondary Sources

Table 65: Key Data Information From Primary Sources

FAQs

1. What is the current Siltuximab market size?

Global Siltuximab market size surpassed USD 410 million in 2023, driven by rising Multicentric Castleman Disease incidence and expanded post-indication usage across major oncology centers worldwide.

2. What is the growth forecast for the Siltuximab market through 2030?

Analysts project a 7.8% CAGR, lifting the Siltuximab market to USD 710 million by 2030, underpinned by label extensions, biosimilar launches, and increasing off-label prescription in cytokine storm syndromes.

3. What are the key demand drivers?

Drivers include limited treatment options for iMCD, strong clinical data on IL-6 inhibition, favorable reimbursement in the U.S. and EU, and emerging use in POEMS and refractory vasculitis.

4. What major challenges restrain wider uptake?

High therapy cost, small patient pool, risk of neutropenia, infusion reactions, and competition with tocilizumab and emerging JAK inhibitors constrain volume growth in the Siltuximab market.

5. Which regions lead revenue generation?

North America commands 58% share due to premium pricing and early adoption; Europe follows at 24% with biosimilar uptake; Asia-Pacific, led by Japan and China, is the fastest-growing regional segment.

6. Who are the top companies shaping the competitive landscape?

Johnson & Johnson (Janssen) markets the originator Sylvant. Celltrion, Pfizer, and Biocon are advancing biosimilars; Sandoz and Amgen follow with late-stage candidates, intensifying price competition post-2026.

7. Where do future opportunities lie?

Future outlook centers on subcutaneous formulations, pediatric iMCD approval, real-world evidence in COVID-19 CRS, combination immuno-oncology trials, and penetration into Latin American and Middle Eastern markets.

8. How is technology impacting production and access?

Single-use bioreactors, continuous perfusion, and high-yield CHO lines cut cost of goods by 30%, enabling emerging-market tenders and supporting sustainable supply for future demand spikes.

9. What does the regulatory landscape look like?

FDA and EMA maintain orphan exclusivity until 2027; WHO prequalification is underway for biosimilars. China NMPA and India CDSCO have tightened comparability protocols, accelerating local biosimilar timelines.

Contact for Full Report

Loading report content...

Which Companies Lead the Siltuximab Market in 2026?

Market Snapshot

Siltuximab Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Siltuximab Segmentation

Siltuximab Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Siltuximab market size?

2. What is the growth forecast for the Siltuximab market through 2030?

3. What are the key demand drivers?

4. What major challenges restrain wider uptake?

5. Which regions lead revenue generation?

6. Who are the top companies shaping the competitive landscape?

7. Where do future opportunities lie?

8. How is technology impacting production and access?

9. What does the regulatory landscape look like?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Siltuximab Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Siltuximab Segmentation

Siltuximab Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Siltuximab market size?

2. What is the growth forecast for the Siltuximab market through 2030?

3. What are the key demand drivers?

4. What major challenges restrain wider uptake?

5. Which regions lead revenue generation?

6. Who are the top companies shaping the competitive landscape?

7. Where do future opportunities lie?

8. How is technology impacting production and access?

9. What does the regulatory landscape look like?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation